2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160434
    TNF-α-IN-13 364039-48-5 98%
    TNF-α-IN-13 is a potent TNFα inhibitor with an IC50 of <0.6 μM. TNF-α-IN-13 has antiinflammatory properties (WO2001072735A2; example 6).
    TNF-α-IN-13
  • HY-160435
    TNF-α-IN-14 364039-54-3 98%
    TNF-α-IN-14 is a potent and selective TNFα inhibitor with an IC50 value of 1.1 µM. TNF-α-IN-14 shows antiinflammatory properties (WO2001072735A2; compound 12).
    TNF-α-IN-14
  • HY-160436
    TNF-α-IN-15 364039-58-7 98%
    TNF-α-IN-15 is a TNF-α inhibitor. TNF-α-IN-15 can decrease the TNF-α blood levels.
    TNF-α-IN-15
  • HY-160437
    TNF-α-IN-16 364039-60-1 98%
    TNF-α-IN-16 is a potent TNFα inhibitor with an IC50 of <0.6 μM. TNF-α-IN-16 has antiinflammatory properties (WO2001072735A2; example 18).
    TNF-α-IN-16
  • HY-160541
    Mal-PEG2000-NHS ester 174459-59-7 98%
    Mal-PEG2000-NHS ester is a PEG linker, can be used to link lipoteichoic acid (LTA) and CpG DNA fragments to synthesis CpG-TA Heterodiners. Mal-PEG2000-NHS ester can be used for immune stimulation research.
    Mal-PEG2000-NHS ester
  • HY-160545
    NLRP3-IN-31 2769040-08-4 98%
    NLRP3-IN-31 (Comp 14) is a NLRP3 inhibitor, with an IC50 of 0.3-0.5 μM.
    NLRP3-IN-31
  • HY-160548
    mTOR inhibitor-18 2170358-67-3 98%
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160585
    PD-L1/PD-1-IN-1 2753642-49-6 98%
    PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of PD-L1/PD interaction, with IC50 ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research.
    PD-L1/PD-1-IN-1
  • HY-160634
    BRD4 Inhibitor-31 1446233-35-7 98%
    BRD4 Inhibitor-31 (Example 136) is a BRD4 inhibitor (Kis: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS.
    BRD4 Inhibitor-31
  • HY-160637
    Lp-PLA2-IN-17 1818842-74-8 98%
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2.
    Lp-PLA2-IN-17
  • HY-160646
    LTA4H-IN-3 2707473-09-2 98%
    LTA4H-IN-3 (compound 9) is a LTA4H inhibitor with the IC50 of 28 nM.
    LTA4H-IN-3
  • HY-160654
    IRAK4 modulator-1 1356014-97-5 99.11%
    IRAK4 modulator-1 (example 161) is a modulator of IRAK4 with IC50=4.647 μM. IRAK4 modulator-1 can be used to study IRAK-mediated disorders.
    IRAK4 modulator-1
  • HY-160663
    Nav1.7 blocker 1 1426336-36-8 98%
    Nav1.7 blocker 1 (example 41) is a Na+ channel (Nav) blocker with an IC50 value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on.
    Nav1.7 blocker 1
  • HY-160676
    sEH-IN-1 1061377-99-8 98%
    sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
    sEH-IN-1
  • HY-160761
    K-Opioid receptor agonist-1 1816990-29-0 98%
    K-Opioid receptor agonist-1 (Compound 5a) is an agonist for κ-Opioid receptor with Ki of 0.25 nM and EC50 of 2 nM. K-Opioid receptor agonist-1 is blood brain barrier (BBB) penetrate (brain/plasma ratios of 0.50 to 0.65). K-Opioid receptor agonist-1 exhibits anti-inflammatory activity in dermatitis models induced by Arachidonic acid (HY-109590) or oxazolidinone.
    K-Opioid receptor agonist-1
  • HY-160789
    C3001a 2415154-29-7
    C3001a is a selective TREK-1 and TREK-2 channel activator with EC50 values of 12.81 μM and 11.31 μM, respectively. C3001a does not affect other two-pore domain K+ (K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a can be used for the study of pain and pancreatitis.
    C3001a
  • HY-160800
    Bilirubin ditaurine 89771-93-7 98%
    Bilirubin ditaurine (BR-DT) is a mimetic compound of conjugated bilirubin. Bilirubin ditaurine can completely prevent the oxidation of phosphatidylcholine induced by reactive oxygen species in multilayer liposomes or micelles. Bilirubin ditaurine does not significantly decompose 18:2-OOH on its own, but it can greatly accelerate the decomposition of 18:2-OOH catalyzed by copper ions. Bilirubin ditaurine can be used to study the detoxification effect of conjugated bilirubin.
    Bilirubin ditaurine
  • HY-160823
    2ccPA sodium 927880-40-8
    2ccPA sodium is a lysophosphatidic acid (LPA) receptor agonist. 2ccPA sodium modulates processes such as cell proliferation, migration, and apoptosis by activating LPA receptors and inhibiting autotaxin (ATX) enzyme activity. 2ccPA sodium is promising for research of cancers, inflammation, and fibrosis.
    2ccPA sodium
  • HY-160824
    Neutrophil elastase-IN-7 6968-33-8 98%
    Neutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC50 value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC50 values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.
    Neutrophil elastase-IN-7
  • HY-160844
    CT-133 2417155-47-4 98%
    CT-133 is a selective and potent CRTH2 Receptor antagonist, with a Ki value of 2.2 nM. The Ki value for the DP1 receptor is greater than 3800 nM. CT-133 inhibits neutrophil migration induced by PGD2 (HY-101988). CT-133 significantly alleviates lung inflammation and improves lung function impairment in a mouse model of acute lung injury (ALI) induced by cigarette smoke. CT-133 effectively inhibits the excessive expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (KC), and reverses the inhibition of the anti-inflammatory factor IL-10. CT-133 can be used for the study of ALI.
    CT-133
Cat. No. Product Name / Synonyms Application Reactivity